NCNA Projected Dividend Yield
ADR (New)/NuCana Plc ( NASDAQ : NCNA )NuCana is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by applying its ProTide™ technology to transform some of the prescribed chemotherapy agents, nucleoside analogs, into medicines. Utilizing its proprietary technology, Co. is developing new medicines, ProTides, designed to overcome main cancer resistance mechanisms and generate concentrations of anti-cancer metabolites in cancer cells. Co.'s ProTide candidates, Acelarin® and NUC-3373, are chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two chemotherapy agents. Co. is evaluating NUC-7738 in clinical trial for patients with solid tumors. 20 YEAR PERFORMANCE RESULTS |
NCNA Dividend History Detail NCNA Dividend News NCNA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |